News headlines about Masimo (NASDAQ:MASI) have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Masimo earned a news impact score of 0.10 on Accern’s scale. Accern also gave news coverage about the medical equipment provider an impact score of 46.0599346253408 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the news articles that may have effected Accern’s rankings:
- Analysts Expect Masimo Co. (MASI) to Post $0.70 Earnings Per Share (americanbankingnews.com)
- Toshiba partners with Atheer to provide enterprise-grade Augmented Reality (AR) software platform for Toshiba’s new dynaEdge™ AR Smart Glasses (bizjournals.com)
- Masimo announces Cairo University researchers evaluate accuracy, trending of its SpHb during acute bleeding and after fluid resuscitation (pharmabiz.com)
- Masimo announces Cairo University researchers evaluate accuracy … – pharmabiz.com (pharmabiz.com)
- New Study Investigates the Performance of Masimo SpHb® During … – Business Wire India (press release) (businesswireindia.com)
A number of research firms have commented on MASI. Barclays began coverage on shares of Masimo in a research report on Friday, March 9th. They issued an “overweight” rating and a $97.00 target price for the company. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $94.00 target price for the company in a research report on Tuesday, March 6th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $91.00 target price on shares of Masimo in a research report on Thursday, March 1st. Finally, BidaskClub raised shares of Masimo from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Masimo currently has a consensus rating of “Buy” and an average target price of $101.00.
Shares of Masimo (NASDAQ:MASI) traded up $1.37 during mid-day trading on Tuesday, hitting $86.87. 430,797 shares of the stock were exchanged, compared to its average volume of 589,274. Masimo has a 12-month low of $80.69 and a 12-month high of $104.71. The company has a market cap of $4,489.78, a P/E ratio of 36.81, a price-to-earnings-growth ratio of 2.28 and a beta of 0.92.
Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.11. Masimo had a net margin of 16.49% and a return on equity of 22.75%. The firm had revenue of $225.20 million during the quarter, compared to the consensus estimate of $201.54 million. During the same quarter in the previous year, the firm posted $0.46 EPS. The company’s revenue for the quarter was up 22.9% compared to the same quarter last year. equities research analysts expect that Masimo will post 2.81 earnings per share for the current year.
In other news, EVP Yongsam Lee sold 10,000 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $92.95, for a total transaction of $929,500.00. Following the completion of the sale, the executive vice president now owns 79,000 shares of the company’s stock, valued at approximately $7,343,050. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Sanford Fitch sold 2,000 shares of the business’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $90.00, for a total transaction of $180,000.00. Following the sale, the director now directly owns 70,249 shares of the company’s stock, valued at approximately $6,322,410. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,100 shares of company stock valued at $2,186,340. Insiders own 13.10% of the company’s stock.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.